Veradermics is trading 4.36% lower at $133.60, with no clear company-specific announcement identified to explain the November 2 decline.

  • Positive Phase 3 Study 304 results were reported October 19; that earlier news does not establish a reason for the decline.
  • The S&P 500 is up 0.88%, the Nasdaq Composite 1.25%, and the Dow 1.07%; the broader market context does not explain the move.
  • Intraday volume information was not available in the supplied price context.